Compare ANGH & EVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ANGH | EVAX |
|---|---|---|
| Founded | 2012 | 2008 |
| Country | United Arab Emirates | Denmark |
| Employees | 191 | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 31.9M | 25.9M |
| IPO Year | 2021 | 2020 |
| Metric | ANGH | EVAX |
|---|---|---|
| Price | $3.52 | $3.12 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $11.67 |
| AVG Volume (30 Days) | 18.1K | ★ 200.0K |
| Earning Date | 05-12-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $328.20 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.25 | $2.71 |
| 52 Week High | $7.89 | $12.15 |
| Indicator | ANGH | EVAX |
|---|---|---|
| Relative Strength Index (RSI) | 52.83 | 49.66 |
| Support Level | $3.13 | $2.91 |
| Resistance Level | $3.90 | $3.62 |
| Average True Range (ATR) | 0.21 | 0.26 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 56.26 | 34.57 |
Anghami Inc is a digital music entertainment technology platform in the Middle East and North Africa, with a catalog of songs. The company features licensed content from Arabic labels, independent artists, and distributors. It also features music from International labels such as Universal, Sony, and Warner Music. The Group's three reportable segments: Revenue from subscriptions, Revenue from advertisement, and Revenue from live events. It generates the majority of its revenue from subscriptions segment, which is comes from subscription fees. The advertisement revenue segment generated through the sale of advertising across the Group's content. Revenues from live events are generated from the sale of tickets, food and beverage & sponsorship. It derives maximum revenue from KSA.
Evaxion AS is a clinical-stage TechBio company developing novel vaccines with its proprietary, clinically validated and scalable AI platform, AI-Immunology. The platform harnesses the power of artificial intelligence to decode the human immune system and develop novel vaccine candidates for cancer and infectious diseases for patients in the market. Evaxion has developed a clinical-stage oncology pipeline of novel personalised vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. The group is committed to transforming patients' lives by providing inventive and targeted treatment options.